GB00BYMT0J19 - Common Stock
LIVANOVA PLC
NASDAQ:LIVN (10/29/2024, 4:30:02 PM)
After market: 52.97 0 (0%)52.97
-0.19 (-0.36%)
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. The company includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
LIVANOVA PLC
20 Eastbourne Terrace
London W2 6LG
P: 442033250662
CEO: Damien McDonald
Employees: 2900
Website: https://www.livanova.com/
LIVN stock results show that LivaNova beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Here you can normally see the latest stock twits on LIVN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: